Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. NTLA Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Intellia Therapeutics (NTLA)

Market Price (9/18/2025): $12.68 | Market Cap: $1.3 Bil
Sector: Health Care | Industry: Biotechnology

Intellia Therapeutics (NTLA)

Market Price (9/18/2025): $12.68
Market Cap: $1.3 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -28%		 Weak multi-year price returns
2Y Excs Rtn is -113%, 3Y Excs Rtn is -142%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -512 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -969%
1   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -792%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -798%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42%
3   Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -28%
1 Weak multi-year price returns
2Y Excs Rtn is -113%, 3Y Excs Rtn is -142%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -512 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -969%
3 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -792%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -798%
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42%
5 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27%

Market Valuation

 9/18/252024202320222021
Share Price CYE$12.68$11.66$30.49$34.89$118.24
Market Cap CYE ($ Bil)1.31.22.82.88.8
Total Debt ($ Bil)0.10.20.10.10.1
Total Cash ($ Bil)0.50.60.91.20.7
Enterprise Value ($ Bil)1.01.42.92.98.9
Valuation Ratios     
P/S TTM24.919.974.651.5253.6
P/EBIT TTM-2.6-2.2-5.2-5.9-31.3
P/E TTM-2.7-2.2-5.6-5.7-31.3
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$12.68$11.66$30.49
Market Cap CYE ($ Bil)1.31.22.8
Total Debt ($ Bil)0.10.20.1
Total Cash ($ Bil)0.50.60.9
Enterprise Value ($ Bil)1.01.42.9
Valuation Ratios   
P/S TTM24.919.974.6
P/EBIT TTM-2.6-2.2-5.2
P/E TTM-2.7-2.2-5.6
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
NTLA Return271%117%-70%-13%-62%6%-22%
Peers Return4%2%25%17%-0%26%96%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: IONS, ABBV, AMGN, GILD, VRTX. See NTLA Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than Intellia Therapeutics (NTLA)

 NTLABetter Performance than NTLA
MetricValueIndustry (Biotechnology)
Rev Chg LTM15.0%ALNY (17.2%), INSM (21.2%), UTHR (17.6%), INCY (18.9%), NBIX (21.7%)
Rev Chg 3Y Avg6.2%AMGN (10.0%), VRTX (11.0%), ALNY (40.8%), INSM (21.6%), UTHR (19.9%)
Op Mgn LTM-968.7%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM-791.9%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-798.0%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield-37.3%ABBV (3.9%), AMGN (7.8%), GILD (7.3%), VRTX (3.7%), REGN (7.5%)
 NTLABetter Performance than NTLA
MetricValueAll Other Sectors
Rev Chg LTM15.0%NVDA (71.6%), META (19.4%), AVGO (28.0%), PLTR (38.8%), AMD (27.2%)
Rev Chg 3Y Avg6.2%NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM-968.7%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-791.9%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-798.0%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-37.3%NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.9%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Intellia Therapeutics (NTLA) EBITDA ComparisonFinancials 
2Intellia Therapeutics (NTLA) Net Income ComparisonFinancials 
3Intellia Therapeutics (NTLA) Revenue ComparisonFinancials 
4Intellia Therapeutics (NTLA) Operating Income ComparisonFinancials 
5Intellia Therapeutics (NTLA) Operating Cash Flow ComparisonFinancials 
6Intellia Therapeutics (NTLA) Debt ComparisonFinancials 
7Intellia Therapeutics (NTLA) Tax Expense ComparisonFinancials 
8NTLA Dip Buy Analysis  
9Intellia Therapeutics (NTLA) Stock: 35% of days in last 3 months had 1% or greater fluctuation  
10Intellia Therapeutics Total Shareholder Return (TSR): -61.8% in 2024 and -53.8% 3-yr compounded annual returns (above peer average)  
11ARTICLES  
12Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month? December 16th, 2022
13Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look November 28th, 2022
14With Recent Advancements, Are Gene Editing Stocks Worth A Look? August 31st, 2022
15Gene Editing Stocks To Consider After Bluebird Bio’s Breakthroughs June 15th, 2022
16Is A Rise Imminent For Intellia Therapeutics Stock After 30% Fall In A Month? March 7th, 2022
Title
0DASHBOARDS
1Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month?
2Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look
3With Recent Advancements, Are Gene Editing Stocks Worth A Look?
4Gene Editing Stocks To Consider After Bluebird Bio’s Breakthroughs
5Is A Rise Imminent For Intellia Therapeutics Stock After 30% Fall In A Month?
6ARTICLES
7Intellia Therapeutics (NTLA) EBITDA Comparison
8Intellia Therapeutics (NTLA) Net Income Comparison
9Intellia Therapeutics (NTLA) Revenue Comparison
10Intellia Therapeutics (NTLA) Operating Income Comparison
11Intellia Therapeutics (NTLA) Operating Cash Flow Comparison
12Intellia Therapeutics (NTLA) Debt Comparison
13Intellia Therapeutics (NTLA) Tax Expense Comparison
14NTLA Dip Buy Analysis
15Intellia Therapeutics (NTLA) Stock: 35% of days in last 3 months had 1% or greater fluctuation
16Intellia Therapeutics Total Shareholder Return (TSR): -61.8% in 2024 and -53.8% 3-yr compounded annual returns (above peer average)

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Intellia Therapeutics

Financials

NTLAIONSABBVAMGNGILDVRTXMedian
NameIntellia.Ionis Ph.AbbVie Amgen Gilead S.Vertex P. 
Mkt Price12.4161.17220.81274.71112.26387.15166.53
Mkt Cap1.39.7390.4147.8139.899.4119.6
Rev LTM5371758,32834,91728,86211,41920,140
Op Inc LTM-512-47213,6958,19210,797-1993,996
FCF LTM-422-56318,23910,6059,3693,5006,434
FCF 3Y Avg-396-43820,2738,5908,3971,9845,191
CFO LTM-419-50219,28312,0139,8683,8466,857
CFO 3Y Avg-387-40121,1549,7538,9492,3245,636

Growth & Margins

NTLAIONSABBVAMGNGILDVRTXMedian
NameIntellia.Ionis Ph.AbbVie Amgen Gilead S.Vertex P. 
Rev Chg LTM15.0%-7.6%6.1%12.9%3.8%10.5%8.3%
Rev Chg 3Y Avg6.2%-1.4%0.6%10.0%1.6%11.0%3.9%
Rev Chg Q104.8%10.1%6.6%9.4%1.8%12.1%9.8%
QoQ Delta Rev Chg LTM16.0%1.7%1.7%2.3%0.4%2.9%2.0%
Op Mgn LTM-968.7%-65.9%23.5%23.5%37.4%-1.7%10.9%
Op Mgn 3Y Avg-991.9%-65.7%27.2%26.4%39.2%26.5%26.5%
QoQ Delta Op Mgn LTM218.7%1.5%1.0%1.6%-0.0%2.0%1.6%
CFO/Rev LTM-791.9%-70.0%33.1%34.4%34.2%33.7%33.4%
CFO/Rev 3Y Avg-766.0%-59.0%37.5%32.0%31.9%22.5%27.2%
FCF/Rev LTM-798.0%-78.5%31.3%30.4%32.5%30.6%30.5%
FCF/Rev 3Y Avg-785.0%-64.4%36.0%28.2%30.0%19.2%23.7%

Valuation

NTLAIONSABBVAMGNGILDVRTXMedian
NameIntellia.Ionis Ph.AbbVie Amgen Gilead S.Vertex P. 
Mkt Cap1.39.7390.4147.8139.899.4119.6
P/S24.413.56.74.24.88.77.7
P/EBIT-2.5-25.766.314.317.022.615.7
P/E-2.7-21.2103.722.322.127.322.2
P/CFO-3.1-19.420.212.314.225.813.2
Total Yield-37.3%-4.7%3.9%7.8%7.3%3.7%3.8%
Dividend Yield0.0%0.0%2.9%3.4%2.8%0.0%1.4%
FCF Yield 3Y Avg-23.9%-7.0%7.3%6.2%8.0%2.1%4.1%
D/E0.10.10.20.40.20.00.2
Net D/E-0.3-0.10.20.30.1-0.00.0

Returns

NTLAIONSABBVAMGNGILDVRTXMedian
NameIntellia.Ionis Ph.AbbVie Amgen Gilead S.Vertex P. 
1M Rtn15.7%40.8%6.9%-6.1%-4.2%-0.7%3.1%
3M Rtn29.3%65.3%20.1%-4.4%4.7%-13.7%12.4%
6M Rtn33.4%83.5%5.9%-11.5%5.9%-24.5%5.9%
12M Rtn-45.0%47.4%18.2%-14.7%39.2%-19.6%1.8%
3Y Rtn-81.1%32.0%71.6%30.8%90.5%33.6%32.8%
1M Excs Rtn13.3%38.5%4.5%-8.5%-6.5%-3.0%0.8%
3M Excs Rtn19.2%58.9%9.8%-14.8%-5.7%-22.7%2.0%
6M Excs Rtn17.5%68.1%-12.4%-29.9%-14.3%-42.0%-13.4%
12M Excs Rtn-61.1%27.7%0.4%-31.9%22.3%-37.6%-15.7%
3Y Excs Rtn-141.5%-34.9%13.2%-33.4%25.2%-28.7%-31.0%

Comparison Analyses

Title
0Intellia Therapeutics vs. Editas Medicine: Neither Seems Like A Good Bet
1Intellia Therapeutics vs. Ionis Pharmaceuticals: With Return Forecast Of 20%, Ionis Pharmaceuticals Is A Better Bet
2Intellia Therapeutics vs. CRISPR Therapeutics: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better Bet
3Intellia Therapeutics vs. Fate Therapeutics: With Return Forecast Of 74%, Fate Therapeutics Is A Better Bet
4Intellia Therapeutics vs. Steelcase: Neither Seems Like A Good Bet
5Intellia Therapeutics vs. AMC Entertainment: Neither Seems Like A Good Bet
6Intellia Therapeutics vs. CommScope: Neither Seems Like A Good Bet
7Intellia Therapeutics vs. Verint Systems: Neither Seems Like A Good Bet
8Intellia Therapeutics vs. Hanesbrands: Neither Seems Like A Good Bet
9Intellia Therapeutics vs. Progress Software: With Return Forecast Of 27%, Progress Software Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/7/20255/8/20252/27/202511/7/20248/8/20245/9/20242/22/202411/9/20238/3/20235/4/20232/23/202311/3/2022
Key Financials Quarterly            
Total Revenue1417139729-21214131413
Ebitda-108-118-134-142-136-111-137-129-130-110-108-104
Operating Income-110-121-136-145-139-114-140-131-132-112-110-106
Net Income-101-114-129-136-147-107-132-122-124-103-113-113
EPS-0.98-1.10-1.27-1.34-1.52-1.12-1.46-1.38-1.40-1.17-1.40-1.49
Key Financials TTM            
Total Revenue TTM534658434653365253535251
Ebitda TTM-502-531-524-528-514-508-506-477-452-418-451-421
Operating Income TTM-512-541-534-538-524-517-515-485-460-426-458-428
Net Income TTM-480-526-519-522-509-486-481-462-453-430-474-442
Growth Rates Quarterly            
Total Revenue Growth104.8%-42.5%771.6%-24.0%-48.8%129.5%-114.1%-9.6%-3.1%12.0%5.6%84.1%
EBITDA Growth21.2%-6.1%2.6%-10.4%-4.8%-1.4%-27.2%-24.4%-34.9%22.9%-37.6%-47.5%
Operating Income Growth20.9%-6.0%2.5%-10.4%-5.1%-1.8%-27.1%-24.2%-34.6%22.4%-36.9%-46.6%
Net Income Growth31.1%-6.4%2.5%-11.0%-18.8%-4.2%-16.5%-7.9%-22.8%29.8%-39.6%-58.0%
Margins Quarterly            
EBITDA Margin-754.8%-711.5%-1039.9%-1560.3%-1961.2%-385.3%--1074.2%-957.5%-871.9%-796.1%-780.8%
Operating Income Margin-772.2%-726.6%-1059.9%-1589.0%-1998.6%-394.0%--1093.3%-973.5%-888.1%-811.1%-795.5%
Net Income Margin-710.8%-687.6%-1001.2%-1489.5%-2112.6%-371.3%--1019.2%-909.8%-818.1%-835.5%-853.5%
Cash & Debt            
Total Cash4605046026586917919128559089341,193828
Total Debt10311921010210611111511812212613198
Net Debt / (Cash)-357-384-391-556-585-680-797-736-786-807-1,062-731
Cash Flows Quarterly            
FCF from Operations-100-149-85-85-58-121-93-101-90-109-90-79
Cash Flows TTM            
FCF from Operations TTM-419-377-349-357-373-405-394-391-368-363-333-298
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-16.0%-18.0%-20.5%-23.6%-24.2%-21.5%-29.3%-28.7%-30.7%-26.9%-32.6%-36.4%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-18.6%-20.1%-20.1%-21.9%-22.8%-24.4%-27.0%-26.6%-26.7%-25.6%-33.9%-37.0%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Development of genome editing-based therapies3652335843
Total3652335843


Price Behavior

NTLA Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta1.362.802.561.351.521.70
Up Beta2.752.482.991.191.221.36
Down Beta0.901.710.870.791.121.43
Up Capture67%371%459%261%214%539%
Bmk +ve Days10223571142415
Stock +ve Days9203263121349
Down Capture144%306%166%159%155%109%
Bmk -ve Days11192754106334
Stock -ve Days12213062127401

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity27,737,890
Short Interest: % Change Since 81520250.0%
Average Daily Volume3,669,340
Days-to-Cover Short Interest7.56
Basic Shares Quantity103,732,000
Short % of Basic Shares26.7%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/7/20250.8%-3.3%6.1%
5/8/202513.6%8.1%11.0%
2/27/20250.6%-13.3%-22.2%
11/7/2024-0.4%0.3%-8.3%
8/8/20245.0%0.9%-7.5%
5/9/20248.1%14.0%-1.2%
2/22/20241.1%22.0%2.9%
11/9/2023-12.3%-6.6%2.0%
...
SUMMARY STATS   
# Positive151410
# Negative91014
Median Positive4.8%8.3%8.6%
Median Negative-6.8%-7.0%-9.0%
Max Positive13.6%22.0%59.9%
Max Negative-12.3%-28.3%-25.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/30/2025
3312025508202510-Q 3/31/2025
12312024227202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024808202410-Q 6/30/2024
3312024509202410-Q 3/31/2024
12312023222202410-K 12/31/2023
93020231109202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022223202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022804202210-Q 6/30/2022
3312022505202210-Q 3/31/2022
12312021224202210-K 12/31/2021
93020211104202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0CHASE WILLIAM J 8222025Buy10.03100,0001,003,0001,350,971Form
1Dulac Edward J IIIEVP, Chief Financial Officer7252025Sell14.027,462104,6171,486,989Form
2Clark ElianaEVP, Chief Technical Officer7032025Sell9.821,02210,036936,524Form
3Dube Michael PVP, Chief Accounting Officer7032025Sell9.952,50324,905568,513Form
4GOODMAN JESSE 7022025Sell9.561,54714,789247,661Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.